Drug Profile

ICT 41

Alternative Names: ICT-41

Latest Information Update: 15 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImCheck Therapeutics
Class Antibacterials; Antivirals; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Butyrophilin inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 Dec 2023 Imcheck Therapeutics has patent protection for 'Antibodies having specificity for BTN2 and uses thereof' in USA
06 Dec 2023 Preclinical trials in Mycobacterial infections in France (Parenteral) prior to December 2023 (ImCheck Therapeutics pipeline, December 2023)
06 Dec 2023 Preclinical trials in Viral infections in France (Parenteral) prior to December 2023 (ImCheck Therapeutics pipeline, December 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com